Trial
NCT03250689
Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Pulmonary Disease, Chronic Obstructive
Intervention
Danirixin
Why stopped
Study terminated due to a change in the benefit-risk profile for danirixin in COPD.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-29